K. Micetich

发表

A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells.

D. Barnes, L. Erickson, K. Micetich, 1985, Cancer research.

The depth of post-treatment perirectal tissue invasion is a predictor of outcome in patients with clinical T3N1M0 rectal cancer treated with neoadjuvant chemoradiation followed by surgical resection.

M. Shoup, G. Abood, A. Walther, 2014, American journal of surgery.

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.

R. Fisher, M. Atkins, G. Weiss, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of a specific DNA repair system and nitrosourea cytotoxicity in resistant human cancer cells.

R. Fisher, D. Barnes, B. Futscher, 1989, Cancer communications.

Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.

M. Atkins, M. Sznol, M. B. Atkins, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erythema with features of seborrheic dermatitis and lupus erythematosus associated with systemic 5-fluorouracil.

M. Massa, K. Micetich, K. Dudley, 1987, Cutis.

Are intravenous fluids morally required for a dying patient?

D. Thomasma, K. Micetich, P. H. Steinecker, 1983, Archives of internal medicine.

SWOG S0809: A phase II trial of adjuvant capecitabine (cap)/gemcitabine (gem) followed by concurrent capecitabine and radiotherapy in extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinoma (GBCA).

Charles R. Thomas, L. Dawson, M. Thomas, 2014 .

Analysis of signal transducer and activator of transcription 3 (STAT3) in gastrointestinal stromal tumors.

S. Alkan, G. Paner, G. Aranha, 2003, Anticancer research.

The Ethical Problems of the Open Label Extension Study

K. Micetich, 1996, Cambridge Quarterly of Healthcare Ethics.

Quenching of DNA:platinum(II) monoadducts as a possible mechanism of resistance to cis-diamminedichloroplatinum(II) in L1210 cells.

K. Kohn, L. Zwelling, K. Micetich, 1983, Cancer research.

Exaggerated Response to Insect Bites An Unusual Cutaneous Manifestation of Chronic Lymphocytic Leukemia

M. Massa, K. Micetich, R. Kolbusz, 1989, International journal of dermatology.

Sweet's syndrome with neurologic manifestations in a patient with esophageal adenocarcinoma: case report and review of the literature

M. Shoup, B. Nickoloff, S. Nagda, 2009, International journal of dermatology.

Reactivation of chronic hepatitis B virus infection by cancer chemotherapy.

J. Hoofnagle, G. Dusheiko, R. Young, 1982, Annals of internal medicine.

Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer.

R. Fisher, B. Futscher, L. Erickson, 1992, Journal of the National Cancer Institute.

Four hundred fifty-three consecutive pancreaticoduodenectomies with pancreaticogastrostomy.

G. Aranha, E. Eguia, M. Borge, 2019, American journal of surgery.

SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.

Charles R. Thomas, L. Dawson, M. Thomas, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma

H. Lenz, A. El-Khoueiry, C. Rankin, 2014, British Journal of Cancer.

Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy.

R. Fisher, K. Micetich, J. Mandard, 1981, The American journal of medicine.

11 – Preclinical and Clinical Experiences with Drug Combinations Designed to Inhibit DNA Repair in Resistant Human Tumor Cells

R. Fisher, L. Erickson, K. Micetich, 1988 .

Carboplatin for advanced colorectal carcinoma: a phase II study.

G. Curt, R. Weiss, S. Creekmore, 1986, Cancer treatment reports.

Phase I-II study of m-AMSA administered as a continuous infusion.

L. Zwelling, R. Young, K. Micetich, 1982, Cancer treatment reports.

A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis.

E. Vokes, H. Hochster, H. Kindler, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytogenetic effects of amsacrine on human lymphocytes in vivo and in vitro.

L. Zwelling, C. Kao-Shan, J. Whang-peng, 1984, Cancer treatment reports.

SWOG 0941: A phase II study of sorafenib and erlotinib in patients (pts) with advanced gallbladder cancer or cholangiocarcinoma.

H. Lenz, A. El-Khoueiry, C. Rankin, 2012 .

Special Section: Rejuvenating Research Ethics

K. Micetich, 2009 .

The Ethics of Competition in Liver Transplantation

D. Thomasma, K. Micetich, J. Brems, 1999, Cambridge Quarterly of Healthcare Ethics.

Continuance of nutritional care in the terminally ill patient.

D. Thomasma, K. Micetich, P. H. Steinecker, 1986, Critical care clinics.